← Product Code [FHN](/submissions/GU/subpart-e%E2%80%94surgical-devices/FHN) · K172985 # Ligation Device (K172985) _Leo Medical Co., Ltd. · FHN · Jun 14, 2018 · Gastroenterology, Urology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/GU/subpart-e%E2%80%94surgical-devices/FHN/K172985 ## Device Facts - **Applicant:** Leo Medical Co., Ltd. - **Product Code:** [FHN](/submissions/GU/subpart-e%E2%80%94surgical-devices/FHN.md) - **Decision Date:** Jun 14, 2018 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 876.4400 - **Device Class:** Class 2 - **Review Panel:** Gastroenterology, Urology - **Attributes:** Therapeutic ## Intended Use The device is designed to be used with an Endoscope to deliver a Ligation Loop designed to prevent or control bleeding following polypectomy of pedunculated polyps. ## Device Story Sterile, single-use endoscopic ligation device; consists of ligation loop and delivery system. Used with endoscope to deliver loop to site of pedunculated polyp post-polypectomy. Operated by physician in clinical setting. Loop deployed to mechanically ligate tissue to control or prevent bleeding. Benefits patient by providing immediate hemostasis during endoscopic procedures. ## Clinical Evidence No clinical data. Bench testing only. Compliance with ISO 10993 (biocompatibility) and ASTM F88/F88M-15 (seal strength) verified. Sterilization validated per ISO 11135. ## Technological Characteristics Single-use endoscopic ligation system. Materials evaluated per ISO 10993. Sterilization: Ethylene Oxide (ISO 11135, SAL 10^-6). Dimensions: 15-40mm open width, 1650-2300mm working length, 2.8mm minimal working channel. Mechanical actuation via delivery system. ## Regulatory Identification A hemorrhoidal ligator is a device used to cut off the blood flow to hemorrhoidal tissue by means of a ligature or band placed around the hemorrhoid. ## Special Controls *Classification.* Class II (special controls). Except for a hemostatic metal clip intended for use in the gastrointestinal tract, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9. ## Predicate Devices - Olympus HX-20-1 Endoscopic Ligator ([K964661](/device/K964661.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo, which features a stylized human figure. To the right of that is the FDA logo, which includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text. June 14, 2018 Leo Medical Co., Ltd. Yunpeng Ma Quality and Registration Director 2 Floor, 10 Building 18 Huashan Road Changzhou City, 213022 Jiangsu Province CHINA Re: K172985 Trade/Device Name: Ligation Device Regulation Number: 21 CFR 876.4400 Regulation Name: Hemorrhoidal ligator Regulatory Class: Class II Product Code: FHN, MND Dated: May 16, 2018 Received: May 18, 2018 Dear Yunpeng Ma: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part {1}------------------------------------------------ 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, # Glenn B. Bell -S Benjamin R. Fisher, Ph.D. for Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K172985 Device Name Ligation Device Indications for Use (Describe) The device is designed to be used with an Endoscope to deliver a Ligation Loop designed to control bleeding following polypectomy of pedunculated polyps. Type of Use (Select one or both, as applicable)X Prescription Use (Part 21 CFR 801 Subpart D) | | Over-The-Counter Use (21 CFR 801 Subpart C) ### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and comblete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ ## Tab #2 510(k) Summary This 510(k) Summary is being submitted in accordance with requirements of Title 21, CFR Section 807.92. The assigned 510(k) Number: K172985 - 1. Date of Preparation: 04/28/2018 - 2. Sponsor Identification #### Leo Medical Co., Ltd. 2 Floor, 10 Building, 18 Huashan Road, Changzhou City, 213022, Jiangsu Province, China Establishment Registration Number: Not yet registered. Contact Person: Yunpeng MA Position: Quality and Registration Director Tel: +86-519-85150750-620 Fax: +86-519-85150790 Email: ypma@leomed.cn - 3. Identification of Proposed Device Trade Name: Ligation Device Common Name: Ligator Device Regulatory Information Regulation Name: Hemorrhoidal ligator Classification: 2 Product Code: FHN Subsequent Product Code: MND Regulation Number: 876.4400 Review Panel: Gastroenterology/ Urology Intended Use Statement: The device is designed to be used with an Endoscope to deliver a Ligation Loop designed to prevent or control bleeding following polypectomy of pedunculated polyps. {4}------------------------------------------------ Device Description The Ligation Device is sterile and single-use, which consists of two main components, ligation loop and delivery system. And these two components provided in different sizes to consist different specifications of ligation device. - 4. Identification of Predicate Device 510(k) Number: K964661 Product Name: Olympus HX-20-1 Endoscopic Ligator - 5. Non-Clinical Test Conclusion Non clinical tests were conducted to verify that the proposed device met all design specifications as was Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards: - > ASTM F88/F88M-15, Standard Test Method for Seal Strength of Flexible Barrier Materials. - > ISO 10993-1:2009+AC2010 Biological evaluation of medical device- Part 1: Evaluation and testing within a risk management process [Including: Technical Corrigendum 1 (2010)] - A ISO 10993-5:2009, Biological Evaluation of Medical Devices -- Part 5: Tests For In Vitro Cytotoxicity. - > ISO 10993-6:2016 Biological Evaluation Of Medical Devices -- Part 6: Tests For Local Effects After Implantation - > ISO 10993-7:2008+AC:2009, Biological Evaluation of Medical Devices - Part 7: Ethylene Oxide Sterilization Residuals. - > ISO 10993-10:2010, Biological Evaluation of Medical Devices - Part 10: Tests for Irritation and Skin Sensitization. - > ISO 10993-11: 2006, Biological Evaluation Of Medical Devices - Part 11: Tests For Systemic Toxicity - A ISO 11135:2014 Sterilization of health-care products-Ethylene Oxide- requirements for the development, validation and routine control of a sterilization process for medical devices - Clinical Test Conclusion 6. No clinical study is included in this submission. - 7. Substantially Equivalent (SE) Comparison {5}------------------------------------------------ | Item | Proposed Device | Predicate Device | | |-------------------------|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------| | Product Code | MND and FHN | MND and FHN | | | Regulation Number | 876.4400 | 876.4400 | | | Class | 2 | 2 | | | Intended Use | The ligation device is intended to prevent or control bleeding following polypectomy of pedunculated polyps. | The Olympus HX-20-1 Endoscopic Ligator has been designed to be used with Olympus endoscopes in delivering a MAJ-254 Standard Ligation Loop or MAJ-340 Small ligation Loop, designed to prevent or control bleeding following polypectomy of pedunculated polyps. | | | Single Use | Yes | Not | | | Configuration | Ligation loop
Delivery system | Loop
FG Handle
Coil sheath | | | Open width | 15, 20, 30, 40mm | 13~30mm | | | Minimal working channel | 2.8mm | 2.8mm | | | Working length | 1650, 1950, 2300mm | 1650~2300mm | | | Performance | Release force, tensile strength, clamping strength | Release force, tensile strength, clamping strength | | | Biocompatibility | Cytotoxicity | No cytotoxicity | Comply with ISO 10993 requirements | | | Sensitization | No sensitization | | | | Irritation | No irritation | | | | Acute Systemic Toxicity | No acute systemic toxicity | | | | Subchronic Systemic Toxicity | No subchronic systemic toxicity | | | | Subcutaneous Implantation | The histological responses around the test sample were similar to the control sample. | | | | Pyrogenicity | No pyrogenicity | | | Sterilization | EO sterilized, SAL 10-6 | Moist heat, SAL 10-6 | | | Shelf life | Two years | No requirement | | | Labeling | Conform to 21 CFR part 801 | Conform to 21 CFR part 801 | | | | | | Table 1 Comparison of Technology Characteristics | |--|--|--|--------------------------------------------------| |--|--|--|--------------------------------------------------| {6}------------------------------------------------ The proposed device and predicate device share similar intended use and performance. The proposed device is single-use, which is sterilized by the manufacturer, and the sterilization cycle has been validated per ISO 11135. The coil sheath and FG handle of predicate device is reusable, and sterilized by user. Because of the re-sterilization, the safety and performance of the predicate devices would be influenced and reduced, and this condition would not be occur to the proposed device, the difference will not affect substantially equivalency. #### 8. Substantially Equivalent (SE) Conclusion Based on the comparison and analysis above, the proposed devices are determined to be Substantially Equivalent (SE) to the predicate devices. --- **Source:** [https://fda.innolitics.com/submissions/GU/subpart-e%E2%80%94surgical-devices/FHN/K172985](https://fda.innolitics.com/submissions/GU/subpart-e%E2%80%94surgical-devices/FHN/K172985) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com